Skip to content
OpenCapital
Get started

Compass Therapeutics, Inc. CMPX Q1 2026 earnings

Reported May 5, 2026 · Before market open

EPS-$0.10In line
Revenue estimate-$818.2K
EPS estimate-$0.10

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate-$600.0K
EPS estimate-$0.10

Versus estimates

Diluted EPS

Q1 2026-$0.10In line
Q4 2025-$0.09Beat by $0.01Q3 2025-$0.08Beat by $0.06Q2 2025-$0.14Miss by $0.01Q1 2025-$0.12In lineQ4 2024-$0.11Miss by $0.01

Ask the moment Compass Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Compass Therapeutics, Inc. report Q1 2026 earnings?
Compass Therapeutics, Inc. (CMPX) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Compass Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Compass Therapeutics, Inc. reported eps of $-0.10 for Q1 2026.
Did Compass Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.10 by $0.00.
How did Compass Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 16.7% from $-0.12.
Where can I find Compass Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-003005) and the 10-Q periodic report (0001171843-26-003006) directly on SEC EDGAR. The filing index links above go to sec.gov.